Skip to content

DOSE FINDING PROSPECTIVE ANALYSIS AFTER HEART SURGERY for Sucrosomial Iron

POSTOPERATIVE SUCROSOMIAL IRON IN HEART SURGERY: DOSE FINDING PROSPECTIVE STUDY (SideralDose)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07038330
Acronym
SideralDose
Enrollment
150
Registered
2025-06-26
Start date
2025-06-23
Completion date
2025-12-31
Last updated
2025-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia

Keywords

Sucrosomial Iron, Oral Iron, Post Cardiac Surgery Rehabilitation

Brief summary

Randomization to different doses of Sucrosomial Iron for one moth after discharge to rehab after heart surgery to assess if more iron grants a faster recovery or not

Detailed description

Evaluation of the efficacy of short-term sucrosomial iron treatment in patients undergoing cardiac surgery and subsequently transferred to rehabilitation, measured in terms of increase in hemoglobin values and restoration of martial blood parameters, administering doses of 30mg, 60mg and 120mg respectively, after randomization of patients. Numerical congruity analysis, power sampling, biometric characteristics of internal compatibility between cohorts and outcome analysis with comparison for continuous homoscedastic case-control variables Drafting of formal statistical analysis, drafting of information synopsis, writing, validation, forwarding to scientific journal and correction until obtaining, where possible, publications of the manuscript relating to the research.

Interventions

Sideral Forte, Italian market formulation of Sucrosomila Iron 30mg per cp

Sponsors

Cardiochirurgia E.H.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

1:1:1 randomization, one month administration,. two months follow up

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Hb\<11; Having had Heart Surgery, Being Discharged to Rehab \-

Exclusion criteria

* Hb\>11.1, hematological primary disesases

Design outcomes

Primary

MeasureTime frameDescription
Hemoglobin30 daysHemoglobin level at 30 day of treatment

Secondary

MeasureTime frameDescription
Martial Metabolism30 daysFerritin, Transferrin, Iron Saturation

Contacts

Primary ContactLuca P Weltert, MD
lweltert@gmail.com+393478880617

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026